|1.||Rivera, Victor M: 4 articles (03/2012 - 11/2009)|
|2.||Gozgit, Joseph M: 3 articles (05/2013 - 06/2011)|
|3.||Clackson, Tim: 3 articles (03/2012 - 11/2009)|
|4.||Shakespeare, William C: 3 articles (03/2012 - 11/2009)|
|5.||Wang, Frank: 3 articles (03/2012 - 11/2009)|
|6.||Wardwell, Scott: 3 articles (03/2012 - 11/2009)|
|7.||Druker, Brian J: 3 articles (11/2011 - 11/2009)|
|8.||Zhu, Xiaotian: 2 articles (04/2013 - 11/2009)|
|9.||Mohemmad, Qurish K: 2 articles (03/2012 - 06/2011)|
|10.||Wong, Matthew J: 2 articles (03/2012 - 06/2011)|
|1.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
11/06/2009 - "AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance."
03/01/2012 - "Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL. "
04/18/2013 - "Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation. "
11/10/2011 - "The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown. "
|2.||Hematologic Neoplasms (Hematological Malignancy)
07/01/2011 - "AP24534 could be the next treatment of choice in hematological malignancies with Philadelphia-positive chromosome, particularly Ph(+) ALL known for its frequent occurrence of T315I mutation."
06/01/2011 - "Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies."
03/01/2012 - "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models."
11/06/2009 - "AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABL(T315I)-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|2.||Adenosine Triphosphate (ATP)
|3.||4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
|4.||dasatinib (BMS 354825)